Hepion Pharmaceuticals, Inc.
HEPA
$0.06
$0.00-1.54%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.86% | -28.55% | -30.90% | -22.03% | -25.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -82.84% | -73.76% | -58.52% | -57.25% | -46.95% |
| Operating Income | 82.84% | 73.76% | 58.52% | 57.25% | 46.95% |
| Income Before Tax | 64.85% | 57.28% | 60.75% | 67.24% | 45.16% |
| Income Tax Expenses | 100.00% | 100.00% | 100.00% | -625.99% | -17.15% |
| Earnings from Continuing Operations | 59.62% | 52.19% | 57.31% | 73.04% | 49.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.62% | 52.19% | 57.31% | 73.04% | 49.18% |
| EBIT | 82.84% | 73.76% | 58.52% | 57.25% | 46.95% |
| EBITDA | 82.90% | 73.76% | 58.45% | 57.26% | 46.96% |
| EPS Basic | 94.01% | 84.73% | 82.45% | 82.39% | 64.25% |
| Normalized Basic EPS | 92.75% | 84.85% | 73.29% | 64.64% | 57.17% |
| EPS Diluted | 94.01% | 84.73% | 82.45% | 82.39% | 64.25% |
| Normalized Diluted EPS | 92.75% | 84.85% | 73.29% | 64.64% | 57.17% |
| Average Basic Shares Outstanding | 5,791.91% | 3,675.76% | 840.92% | 54.66% | 43.93% |
| Average Diluted Shares Outstanding | 5,791.91% | 3,675.76% | 840.92% | 54.66% | 43.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |